Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Aytu BioScience.

    Client Virtual Booth

    AYTU BIOSCIENCE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Formulations

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Aytu BioScience
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    373 Inverness Parkway, Suite 206 Englewood, CO 80112
    Telephone
    Telephone
    +1 855-298-8246
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aytubio.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Denovo's Licenses DB102 (Enzastaurin) for Rare Genetic Pediatric Onset Disorders to Aytu BioPharma

    Details:

    Aytu BioPharma has acquired substantially all the assets of Rumpus Therapeutics, including Rumpus' option to license DB102 for rare genetic pediatric onset or congenital disorders outside of oncology from Denovo Biopharma LLC.


    Lead Product(s): Enzastaurin

    Therapeutic Area: Genetic Disease Product Name: DB102

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Denovo Biopharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 13, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics

    Details:

    Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications. Program initially targeting vascular Ehlers-Danlos Syndrome (vEDS).


    Lead Product(s): Enzastaurin

    Therapeutic Area: Genetic Disease Product Name: AR101

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Recipient: Rumpus Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement April 12, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement

    Details:

    Aytu adds Neos' established, multi-brand ADHD portfolio which includes Adzenys XR-ODT and Cotempla XR-ODT, enhancing Aytu's footprint in pediatrics and expanding its presence in adjacent specialty care segments.


    Lead Product(s): Methylphenidate

    Therapeutic Area: Psychiatry/Psychology Product Name: Cotempla XR-ODT

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Neos Therapeutics

    Deal Size: $44.9 million Upfront Cash: Undisclosed

    Deal Type: Merger December 10, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration

    Details:

    With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and will be able to be commercialized and supplied within Australia.


    Lead Product(s): Zolpidem Tartrate

    Therapeutic Area: Sleep Product Name: Zolpimist

    Highest Development Status: ApprovedProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 30, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search